How to Cite
Abstract
Background: histoplasmosis is a fungic infectious disease described for the first time in Panama by the specie Histoplasma capsulatum, a dimorphic fungus endemic from the fluvial valleys from America, the disease is developed in very few persons mostly in those with deficience in their celular inmunity particularly with HIV. The International Guidelines define the first line of therapy against histoplasmosis with Liposomal Amphotericin B therapy until the clinical condition improve, and then switched to itraconazole for at least 12 months.
Objetive: to know the characteristics of the patients with histoplasmosis at Hospital San Juan de Dios and to state the value of the combined use of amphotericin B deoxycholate and fluconazole as alternative therapy to liposomal amphotericin and itraconazole. Methods: It was made a retrospective study with histoplasmosis positive cases in 2008 to 2012 attended in the Hospital San Juan de Dios, obtained from laboratory and HIV local group files. It was founded 36 cases, and for archive technical reasons we only had access to review 15 clinical records. This study had the local bioethical and research commission approval. The statistical analysis was made in Excell 2007 through the estimation of absolute and relative frecuencies of the variables of interest. Results: this is the case of 15 patients with the
diagnosis of histoplasmosis made by culture and direct observation in bone marrow samples, and only one by biopsy. A 60 % were male, the average age of the infection onset nearby 35 years old, 86,7 % corresponded to HIV patients among which the mean of lymphocites CD4 was 60 cells/mm3. The 15 patients have acute progressive disseminated histoplasmosis as clinical presentation, and two also have intestinal involve. Only two patients had a histoplasmosis relapse and both with HAART desertion associated. Conclusions: it was founded the combination of Amphotericin B deoxycholate, fluconazole and HAART with good clinical outcome in 86,5% with a year relapse free. This combination of HAART and a second line treatment for histoplsmosis with fluconazole was effective, avoiding the bioavailability issues and drug interactions with the itraconazole, particularly in HIV patients. MÉD.UIS. 2014;27(3):19-26.
Keywords: Histoplasmosis. HIV infections.Anti- HIV Agents. Fluconazole. Amphotericin B.
References
Kauffman C. Histoplasmosis a Clinical and Laboratory Up date. Clin Microb Rev. 2007;20:115-32.
Mandell G, Benett J y Dolin F. Principles and Practice of Infectious Diseases. 7ma edición. Churchill Livingston Elsevier: Philadelphia; 2010.
Kauffman C. Diagnosis of Histoplasmosis in immunosuppressed patients. Curr Opin Infec Dis. 2008;21:421-25.
Fernández C, Illnait M, Martinez G, Perurena M y Monroy E. Una
actualización acerca de histoplamosis. Rev Cubana Med Trop. 2011;63(3):189-205.
Wheat LJ, Freifeld AG, Kleiman MB, Braddley JW, McKinsey DS,Loyd JE et al. Clinical Practice Guidelines for the management of patients with histoplasmosis: 2007 Update by the Infectious Disease Society of America. Clin Infect Dis. 2007;45(7):807-25.
Gutierrez ME, Canton A, Sosa N, Puga E y Talavera L. Disseminated Histoplasmosis in Patients with AIDS in Panama: A review of 104 cases. Clin Infect Dis. 2005;40(8):1199-202.
Wheat LJ, Chetchotisakd P, Williams B, Connolly P, Shutt K y Hajjeh R. Factors associated with severe manifestations of histoplasmosis in AIDS. Clin Infect Dis. 2000;30(6):877-81.
Hage CA, Ribes JA, Wengenack NL, Baddour LM, Assi M, McKinsey DS, et al. A multicenter evaluation of tests for diagnosis of Histoplasmosis. Clin Infect Dis. 2011;53(5):448-54.
Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H. Guidelines for prevention and Treatment of Opportunistic Infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58(RR-4):1-207.
Brilhante RS, Fechine MA, Cordeiro RdeA, Rocha MF, Ribeiro JF, Monteiro AJ, et al. In vitro effect of sulfamethoxazoletrimethoprim against histoplasma capsulatum var. capsulatum. Antimicrob Agents Chemother. 2010;54(9):3978-79.
Crommentuyn KM, Mulder JW, Sparidans RW, Huitema AD, Schellens JH, Beijnen JH. Drug-Drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1 infected patient with disseminated histoplasmosis. Clin Infect Dis. 2004;15(38):e73-5.
Koo H, Hamill R, Andrade R. Drug-Drug interaction between Itraconazole and Efavirenz in a patient with AIDS and disseminated Histoplasmosis. Clin Infect Dis. 2007;45(6):e77-9.
Hills-Nieminen C, Hughes CA, Houston S, Shafran SD. Drug drug interaction between itraconazole and the protease inhibidor lopinavir /ritonavir. Ann Pharmacother. 2009;43(12):2117-20.
McKinsey DS, Kauffman CA, Pappas P G, Cloud GA, Girard WM,Sharkey PK, et al. Fluconazole Therapy for Histoplasmosis. Clin Infect Dis. 1996;23(5):996-1001.
Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute renal injury. Crit Care. 2007;11(2):R31.
Tobon A, Medina A, Orozco L, Restrepo C, Molina D, de Bedout C, et al. Histoplasmosis diseminada progresiva en una cohorte de pacientes coinfectados con el VIH. Acta Med Colomb. 2011;36(2):63-
Hernández H, Solano A, Carrillo P. Histoplasmosis en pacientes
con infección por VIH en un hospital de Costa Rica; estudio
comparativo. La Gaceta de Infectología y Microbiología Clínica Latinoamericana. 2012;2(2):16-31.
Wheat J, MaWhinney S, Hafner R, McKinsey D, Chen D, Korzun A, et al. Treatment of Histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. Am J Med. 1997;103(3):223-32.
Vargas C, Boza R. Condición inmunológica de los pacientes portadores de VIH/SIDA en el momento de su diagnóstico en el Hospital San Juan de Dios. Acta Med Costarric. 2012;154(3):159-64.
Johnson PC, Wheat LJ, Cloud GA, Goldman M, Lancaster D, MBamberger DM, et al. Safety and Efficacy of Liposomal Amphotericin B compared with conventional amphotericin B for induction therapy of Histoplasmosis in patients with AIDS. Ann Intern Med. 2002;137(2):105-9.
Tobón AM, Agudelo CA, Rosero DS, Ochoa JE, De Bedout C, Zuluaga A, et al. Disseminated Histoplasmosis: A comparative study between patients with Acquired immunodeficiency syndrome and non human immunodeficiency virus infected individuals. Am J Trop Med Hyg. 2005;73(3):575-82.
Wheat LJ, Connolly P, Smedema M, Brizendine E, Hafner; AIDS Clinical Trials Group, The Mycoses Study Group. Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome. Clin Infect Dis. 2001;33(11):1910-3.
Kurowski R, Ostaochuk M. Overview of Histoplasmosis. Am Fam Physician. 2002;66(12):2247-52.